Venture Capital in Biotechnology
Matherne, G. (Paul...
Venture Capital in Biotechnology
Matherne, G. (Paul); Herpfer, Christoph; Dow, Ethan
OM-1796 | Published December 5, 2023 | 8 pages Technical Note
Collection: Darden School of Business
Product Details
Pharmaceutical companies have historically relied on their ability to research, develop, manufacture, and sell drug products. Developing a successful drug is a complex and lengthy process, with no guarantee of success, and the total cost of approving a new drug is estimated at $2.5 billion, and rising. This technical note offers an overview of changes in the biotechnology industry related to drug development, focusing on M&A, the milestone model, and venture capital.
0
Products to Upsell
Chains
Larson, Andrea
Terminal Values, Multiples, and Competit...
Harris, Robert S.
Leading with Vulnerability
Belmi, Peter; Thom...
Accounting for Owners’ Equity
Lynch, Luann J.; B...
Share Repurchases
Loutskina, Elena
Finance People
Schill, Michael J.
Ought to "Can": Questions for an Entrepr...
Sarasvathy, Saras ...
Jonathan Virginia, Inc.
Hess, Edward D.